Module 1: From Alerts to Answers: Navigating In Silico Genotoxicity Screening and Risk Assessment
Recorded On: 02/24/2027
This module introduces the use of in silico screening tools, including QSAR-based models, with the main focus on supporting risk assessment and decision-making. The session provides background on commonly used in silico assays, their regulatory context, and when these tools are most appropriately implemented across discovery and development. Emphasis is placed on understanding the drivers of positive results, including structural alerts, assay limitations, and model applicability domains. The module additionally discusses the evaluation of nitrosamines, including differences between guideline-based and literature-derived acceptable intake limits, the use of compound-specific cutoffs, and the integration of indication, dosing level, and dosing duration into a holistic risk assessment. Additional topics include the identification and evaluation of impurities, the use of expert-rule and statistical models to support regulatory justification, the importance of training datasets, and factors influencing model selection at different development stages. Case studies are used to illustrate interpretation of outcomes and next steps, including establishing acceptable levels, revisiting chemistry and SAR, or determining when additional testing is warranted. Additional considerations to read-across and analog reasoning for known compounds, TTC framework, and context of human relevance are discussed.
Joel Bercu, PhD, MPH, DABT
Executive Director in the Nonclinical Safety and Pathobiology Group
Gilead Sciences, Inc.
Dr. Joel Bercu is an Executive Director in the Nonclinical Safety and Pathobiology group at Gilead Sciences and has over 25 years of public health and toxicology experience in pharmaceuticals. His mission while at these positions is to protect the safety of staff, patients, and the environment. He leads the Environmental and Occupational Toxicology (EOT) group at Gilead. Part of the remit of the EOT group is pharmaceutical safety impurity assessments (including mutagenic / carcinogenic impurities), QSAR assessments of impurities for ICH M7 compliance, and the safety evaluation of potential nitrosamine impurities. Prior to joining Gilead Sciences, he worked at Eli Lilly and Amgen. He is a member of the Society of Toxicology and the Risk Assessment, Occupational and Public Health (where he served as President and Endowment Steward), Computational Toxicology and Medical Devices Specialty Sections, and the American College of Toxicology (ACT). He is currently on the ICH M7 Nitrosamine Addendum Expert Working Group (EWG) and leads several external committees such as chairing the IQ/DruSafe Impurities Working Group and leading the Nitrosamine Research Program at the Health and Environmental Sciences Institute (HESI). He received his BS from Texas A&M University, MPH from the University of Texas – Houston School of Public Health, PhD from Indiana University, and is a Diplomate of the American Board of Toxicology (DABT).